The FDA has expanded the indication for a drug formerly approved for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections.
The US Food and Drug Administration has approved a new treatment option for adult patients with complicated urinary tract infections, including pyelonephritis.
After clinical trials demonstrated its efficacy and safety, a new treatment option for children with Chagas disease has been approved by the US Food and Drug Administration.